Methinks CTA LVO
AI detection of Large Vessel Occlusions from Contrast CT scans
Software · Cloud SaaSCompany source
Company profile
About Methinks Software S.L.
Methinks Software S.L. is a Barcelona-based health AI company focused on revolutionizing acute stroke care through artificial intelligence. The company's vision is that every stroke patient has access to timely treatment, addressing the critical challenge that advanced imaging like CTA is only available in less than 50% of hospitals worldwide, and CTP in less than 5%. Methinks has developed AI modules that detect Large Vessel Occlusions (LVO) and intracranial hemorrhages (ICH) from non-contrast CT (NCCT) scans—the most universally available imaging modality in hospitals. Their NCCT LVO detection achieves 76.4% sensitivity and 91.1% specificity, while their ICH detection demonstrates 94.7% sensitivity and 99.5% specificity. The company also offers CTA-based LVO detection for hospitals with contrast imaging capabilities. The platform integrates directly with Microsoft Teams to facilitate stroke team coordination, providing AI alerts, team communication tools, video conferencing, and advanced image viewing capabilities. This integration ensures high security standards while making the technology simple to adopt. Methinks has received FDA clearance for both non-contrast and contrast imaging solutions, and holds ISO 27001 and ENS cybersecurity certifications. The company's technology has been validated in peer-reviewed publications and is being used by leading stroke centers including Advocate Aurora Health and Hospital Vall d'Hebron in Barcelona.
Company description Methinks Software S.L. official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Methinks Software S.L.?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Acute ischemic stroke
- Intracranial hemorrhage (ICH)
- Large Vessel Occlusion (LVO)
- M2 occlusions
Who it serves
- Health Systems
- Hospitals
- Stroke Centers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: Microsoft Teams.
Geographic context
MarketsEurope · Spain · United States
Company sourceOfficial website
Company milestones
Platform expansion
Second FDA clearance for contrast imaging (October 2025), ISO 27001 certification (April 2026), ENS cybersecurity certification (February 2026), €2.19M public-private funding for Neuro-rescue project (April 2026)
Partnerships
Recorded partners
- Advocate Aurora Health
- Cooper University Healthcare
- Hospital Vall d'Hebron
- Microsoft Teams integration
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Methinks NCCT ICH
AI detection of Intracranial Hemorrhages from Non-Contrast CT scans
Software · Cloud SaaSCompany source
Methinks NCCT Ischemia
AI estimation of ischemic core volume on Non-Contrast CT
Software · Cloud SaaSCompany source
Methinks NCCT LVO
AI detection of Large Vessel Occlusions from Non-Contrast CT scans
Software · Cloud SaaSCompany source
Methinks Teams Integration
Stroke coordination platform integrated with Microsoft Teams
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Methinks CTA StrokeK251590 · 510k · Aug 20, 2025
Methinks NCCT StrokeK250685 · 510k · Jun 16, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
76.4% sensitivity, 91.1% specificity for NCCT LVO detection
Detection of Large Vessel Occlusions from non-contrast CT
94.7% sensitivity, 99.5% specificity for ICH detection
Detection of intracranial hemorrhages from non-contrast CT
Reduced need for CTA imaging
Enabling stroke detection with universally available NCCT
Increased efficiency of patient transfers
Stroke network coordination
U.S. Multi-facility Stroke Network
LVO detection using NCCT to reduce interpretation time in acute settings
Significant reduction in diagnostic time and potential to save 40 minutes by taking patients directly to angiosuite
Mexico Comprehensive Stroke Centre
Stroke triage in low and middle income countries using NCCT LVO and ICH detection
100% sensitivity and 95.8% specificity, saving 40 minutes of CTA acquisition time
Advocate Aurora Health
Earliest possible diagnosis for indicating thrombectomy in stroke cases
Essential efficiency when every passing second makes a difference in patient lives
Cooper University Healthcare
Acute stroke patient selection for thrombectomy using simplest, fastest imaging modalities
Revolutionary approach to acute stroke care
Hospital Vall d'Hebron
Research implementation of Methinks AI for stroke detection
Outstanding results making team optimistic about future of technology
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Demetrius Lopes
Director Stroke Network
Tudor Jovin
Chairman and Chief of Neurology
Marc Ribó
Stroke Neurologist and Interventionalist
06 · Company updates
Updates from Methinks Software S.L.
Recent articles published on Methinks Software S.L.'s official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.